-+ 0.00%
-+ 0.00%
-+ 0.00%

CDW Reports Favorable Repeat-Dose Results for LNP-LANFA in Mouse Studies

PUBT·11/12/2026 11:13:24
CDW Reports Favorable Repeat-Dose Results for LNP-LANFA in Mouse Studies
  • CDW Holding reported positive follow-up mouse study results for its LNP-LANFA drug-delivery platform on November 12, 2026.
  • Results showed a more favorable spleen-to-liver reporter-expression profile than conventional PEG-modified nanoparticles following repeated dosing, supporting further preclinical development.
  • The studies did not establish therapeutic efficacy, safety or suppression of accelerated blood clearance.
  • Several pharmaceutical companies are nearing completion of independent evaluations, potentially opening licensing and co-development negotiations; no definitive agreements have been signed.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CDW Holding Limited published the original content used to generate this news brief via Singapore Exchange Limited (SGX) (Ref. ID: OZXW94KPNO3ZQHB2) on November 12, 2026, and is solely responsible for the information contained therein.